RU2015133171A - Бензиламиновые производные - Google Patents
Бензиламиновые производные Download PDFInfo
- Publication number
- RU2015133171A RU2015133171A RU2015133171A RU2015133171A RU2015133171A RU 2015133171 A RU2015133171 A RU 2015133171A RU 2015133171 A RU2015133171 A RU 2015133171A RU 2015133171 A RU2015133171 A RU 2015133171A RU 2015133171 A RU2015133171 A RU 2015133171A
- Authority
- RU
- Russia
- Prior art keywords
- ylmethyl
- benzylamide
- aminomethyl
- carboxylic acid
- methyl
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 10
- -1 - (CH 2 ) 1 -3- aryl Chemical group 0.000 claims 8
- 125000002757 morpholinyl group Chemical group 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 7
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 235000010290 biphenyl Nutrition 0.000 claims 5
- 239000004305 biphenyl Substances 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 150000004292 cyclic ethers Chemical class 0.000 claims 3
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010019860 Hereditary angioedema Diseases 0.000 claims 2
- 208000001953 Hypotension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229930195733 hydrocarbon Natural products 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- ZQYKZHHAAMTVKK-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-2,5-dimethyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C(C)=C(C(=O)NCC=2C=CC(CN)=CC=2)C=C1C ZQYKZHHAAMTVKK-UHFFFAOYSA-N 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000008728 vascular permeability Effects 0.000 claims 2
- 230000004304 visual acuity Effects 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- QIDSSXMLJRPBOF-UHFFFAOYSA-N [4-(aminomethyl)-3,5-dimethylphenyl]methanamine Chemical compound CC1=CC(CN)=CC(C)=C1CN QIDSSXMLJRPBOF-UHFFFAOYSA-N 0.000 claims 1
- JNEWOGWYCBIRAE-UHFFFAOYSA-N [4-(aminomethyl)-3-methylphenyl]methanamine Chemical compound CC1=CC(CN)=CC=C1CN JNEWOGWYCBIRAE-UHFFFAOYSA-N 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- ASPQAQDFTSKEAM-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[(2-methylquinolin-6-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=CC2=NC(C)=CC=C2C=C1CN(N=C1C(F)(F)F)C=C1C(=O)NCC1=C(C)C=C(CN)C=C1C ASPQAQDFTSKEAM-UHFFFAOYSA-N 0.000 claims 1
- YWMLIFJICOBECK-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[(2-pyrrolidin-1-ylpyridin-4-yl)methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound CC1=CC(CN)=CC(C)=C1CNC(=O)C(C(=N1)C(F)(F)F)=CN1CC1=CC=NC(N2CCCC2)=C1 YWMLIFJICOBECK-UHFFFAOYSA-N 0.000 claims 1
- KODUDZPOXFRWEI-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C(=CC(CN)=CC=2C)C)=C1 KODUDZPOXFRWEI-UHFFFAOYSA-N 0.000 claims 1
- SEKJKDZFHSHSNB-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C=C(C(=O)NCC=2C(=CC(CN)=CC=2C)C)N=C1 SEKJKDZFHSHSNB-UHFFFAOYSA-N 0.000 claims 1
- NVKWHXBTNJQAIY-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=CC(C(=O)NCC=2C(=CC(CN)=CC=2C)C)=C1 NVKWHXBTNJQAIY-UHFFFAOYSA-N 0.000 claims 1
- TWZMQQMXQBBUHW-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]triazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=NC(C(=O)NCC=2C(=CC(CN)=CC=2C)C)=C1 TWZMQQMXQBBUHW-UHFFFAOYSA-N 0.000 claims 1
- ZQOCYURDVRRUQT-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-1-ethyl-4-methyl-5-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxamide Chemical compound CC=1C=C(C(=O)NCC=2C(=CC(CN)=CC=2C)C)N(CC)C=1CC(C=C1)=CC=C1CN1C=CC=CC1=O ZQOCYURDVRRUQT-UHFFFAOYSA-N 0.000 claims 1
- XFFLHTLNQQRHNA-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=C(C)C=C(CN)C=C1C XFFLHTLNQQRHNA-UHFFFAOYSA-N 0.000 claims 1
- DNOYFEGEXZEIGB-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-2,5-dimethyl-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2C=CC(CN3C(C=CC=C3)=O)=CC=2)C(C)=CC=1C(=O)NCC1=C(C)C=C(CN)C=C1C DNOYFEGEXZEIGB-UHFFFAOYSA-N 0.000 claims 1
- NKFYMWBVMOGCMS-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-3-methyl-1-[(2-methylquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound CC1=NN(CC=2C=C3C=CC(C)=NC3=CC=2)C=C1C(=O)NCC1=C(C)C=C(CN)C=C1C NKFYMWBVMOGCMS-UHFFFAOYSA-N 0.000 claims 1
- SVWVNWWLYZGNGT-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-5-methyl-1-[(2-methylquinolin-6-yl)methyl]pyrazole-4-carboxamide Chemical compound C1=NN(CC=2C=C3C=CC(C)=NC3=CC=2)C(C)=C1C(=O)NCC1=C(C)C=C(CN)C=C1C SVWVNWWLYZGNGT-UHFFFAOYSA-N 0.000 claims 1
- FKHUEKYDJMRASN-UHFFFAOYSA-N n-[[4-(aminomethyl)-2,6-dimethylphenyl]methyl]-5-methyl-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C(C)=C(C(=O)NCC=2C(=CC(CN)=CC=2C)C)C=N1 FKHUEKYDJMRASN-UHFFFAOYSA-N 0.000 claims 1
- GSVROUVRXWFULX-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-(trifluoromethyl)phenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1C(F)(F)F GSVROUVRXWFULX-UHFFFAOYSA-N 0.000 claims 1
- LXZGTPFYSZITPH-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-chlorophenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1Cl LXZGTPFYSZITPH-UHFFFAOYSA-N 0.000 claims 1
- UNKAHMHMAXWBRJ-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-fluorophenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1F UNKAHMHMAXWBRJ-UHFFFAOYSA-N 0.000 claims 1
- IBULPWHWUWJTMW-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-methoxyphenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound COC1=CC(CN)=CC=C1CNC(=O)C1=C(C)N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=C1 IBULPWHWUWJTMW-UHFFFAOYSA-N 0.000 claims 1
- YJGCZOIOIYXKFC-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]triazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=NC(C(=O)NCC=2C(=CC(CN)=CC=2)C)=C1 YJGCZOIOIYXKFC-UHFFFAOYSA-N 0.000 claims 1
- WERWYUINAJCXQE-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-methylphenyl]methyl]-1-ethyl-4-methyl-5-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxamide Chemical compound CC=1C=C(C(=O)NCC=2C(=CC(CN)=CC=2)C)N(CC)C=1CC(C=C1)=CC=C1CN1C=CC=CC1=O WERWYUINAJCXQE-UHFFFAOYSA-N 0.000 claims 1
- LRLXLIQZQCBDLR-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-methylphenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1C LRLXLIQZQCBDLR-UHFFFAOYSA-N 0.000 claims 1
- LJVGJJDTMUPYFI-UHFFFAOYSA-N n-[[4-(aminomethyl)-2-methylphenyl]methyl]-2,5-dimethyl-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2C=CC(CN3C(C=CC=C3)=O)=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1C LJVGJJDTMUPYFI-UHFFFAOYSA-N 0.000 claims 1
- PKZHZUNPMZRBCV-UHFFFAOYSA-N n-[[4-(aminomethyl)-3-fluoro-2-methylphenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C(=C(F)C(CN)=CC=2)C)=C1 PKZHZUNPMZRBCV-UHFFFAOYSA-N 0.000 claims 1
- KVZULUTYGQJNAW-UHFFFAOYSA-N n-[[4-(aminomethyl)-3-fluorophenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=C(C(F)(F)F)C(C(=O)NCC=2C=C(F)C(CN)=CC=2)=C1 KVZULUTYGQJNAW-UHFFFAOYSA-N 0.000 claims 1
- ICSBZJSGYBSVLI-UHFFFAOYSA-N n-[[4-(aminomethyl)-3-fluorophenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C(F)=C1 ICSBZJSGYBSVLI-UHFFFAOYSA-N 0.000 claims 1
- RGTMXBFSDAULGX-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-[[2-(3-fluorophenyl)-1,3-thiazol-4-yl]methyl]-2,5-dimethylpyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=C(F)C=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1 RGTMXBFSDAULGX-UHFFFAOYSA-N 0.000 claims 1
- XWRFLHKXCPPUJD-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]imidazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1C=C(C(=O)NCC=2C=CC(CN)=CC=2)N=C1 XWRFLHKXCPPUJD-UHFFFAOYSA-N 0.000 claims 1
- HPJLQUVYLPKVEH-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=CC(C(=O)NCC=2C=CC(CN)=CC=2)=C1 HPJLQUVYLPKVEH-UHFFFAOYSA-N 0.000 claims 1
- QYIHBTUUQFBDIT-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]triazole-4-carboxamide Chemical compound C1=C(C)C=NN1CC(C=C1)=CC=C1CN1N=NC(C(=O)NCC=2C=CC(CN)=CC=2)=C1 QYIHBTUUQFBDIT-UHFFFAOYSA-N 0.000 claims 1
- ULZKXPDTHIUETL-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-ethyl-4-methyl-5-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxamide Chemical compound CC=1C=C(C(=O)NCC=2C=CC(CN)=CC=2)N(CC)C=1CC(C=C1)=CC=C1CN1C=CC=CC1=O ULZKXPDTHIUETL-UHFFFAOYSA-N 0.000 claims 1
- APSRMPANLLTMGB-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-1-ethyl-4-methyl-5-[[4-[(4-methylpyrazol-1-yl)methyl]phenyl]methyl]pyrrole-2-carboxamide Chemical compound CCN1C(C(=O)NCC=2C=CC(CN)=CC=2)=CC(C)=C1CC(C=C1)=CC=C1CN1C=C(C)C=N1 APSRMPANLLTMGB-UHFFFAOYSA-N 0.000 claims 1
- SJVAITNWGSDKNM-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-2,5-dimethyl-1-[(2-phenyl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1 SJVAITNWGSDKNM-UHFFFAOYSA-N 0.000 claims 1
- NJTXQIBROXFAJJ-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-2,5-dimethyl-1-[(2-thiophen-3-yl-1,3-thiazol-4-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(SC=2)C2=CSC=C2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1 NJTXQIBROXFAJJ-UHFFFAOYSA-N 0.000 claims 1
- ANTXTTKCONNLSC-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-2,5-dimethyl-1-[(6-phenylpyridin-2-yl)methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2N=C(C=CC=2)C=2C=CC=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1 ANTXTTKCONNLSC-UHFFFAOYSA-N 0.000 claims 1
- KVCQGKXGOOUPLT-UHFFFAOYSA-N n-[[4-(aminomethyl)phenyl]methyl]-2,5-dimethyl-1-[[4-[(2-oxopyridin-1-yl)methyl]phenyl]methyl]pyrrole-3-carboxamide Chemical compound CC=1N(CC=2C=CC(CN3C(C=CC=C3)=O)=CC=2)C(C)=CC=1C(=O)NCC1=CC=C(CN)C=C1 KVCQGKXGOOUPLT-UHFFFAOYSA-N 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Claims (123)
1. Соединение формулы (I),
где
V выбран из С и N так, что ароматическое кольцо, содержащее V, представляет собой фенил или пиридин;
R2 отсутствует, когда V представляет собой N; или, когда присутствует, R2 выбран из Н, алкила, алкокси, CN, галогена и CF3;
R1 и R3 независимо выбраны из Н, алкила, алкокси, CN, галогена и CF3;
W, X, Y и Z независимо выбраны из С, N, О и S, так, что кольцо, содержащее W, X, Y и Z, представляет собой пяти-членный ароматический гетероцикл;
где
R5, R6 и R7 независимо отсутствуют или независимо выбраны из Н, алкила, галогена, арила, гетероарила и CF3;
Р представляет собой -C(R10)(R11)NH2;
R8 и R9 независимо выбраны из Н и алкила, или могут вместе образовывать циклоалкильное кольцо;
R10 и R11 независимо выбраны из Н и алкила, или могут вместе образовывать циклоалкильное кольцо или циклический эфир;
А выбран из N-связанного морфолина, арила, гетероарила,
алкил представляет собой линейный насыщенный углеводород, содержащий до 10 атомов углерода (C1-C10), или разветвленный насыщенный углеводород, содержащий от 3 до 10 атомов углерода (С3-С10); алкил, необязательно, может быть замещен 1 или 2 заместителями, независимо выбранными из (C1-C6)алкокси, ОН, CN, CF3, -COOR12, -CONR12R13, Н(СН2)1-3CON(R12)(CH2)1-3-, фтор и
-NR12R13;
циклоалкил представляет собой моноциклический насыщенный углеводород, содержащий от 3 до 7 атомов углерода; при этом циклоалкил, необязательно, может быть замещен заместителем, выбранным из алкила, алкокси и NR12R13;
циклический эфир представляет собой моноциклический насыщенный углеводород, содержащий от 4 до 7 атомов углерода, где один из кольцевых атомов углерода замещен атомом кислорода;
алкокси представляет собой линейный О-связанный углеводород, содержащий от 1 до 6 атомов углерода (C1-C6), или разветвленный O-связанный углеводород, содержащий от 3 до 6 атомов углерода (С3-С6); алкокси, необязательно, может быть замещен 1 или 2 заместителями, независимо выбранными из арила, ОН, CN, CF3, -COOR12, -CONR12R13, фтора и NR12R13;
арил представляет собой фенил, бифенил или нафтил; арил, необязательно, может быть замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, ОН, галогена, CN, -морфолинила, -пиперидинила, гетероарила, арилаb, -O-арилаb, -(СН2)1-3-арилаb, -(СН2)1-3-гетероарила, -COOR12, -CONR12R13, -(CH2)1-3-NR14R15, CF3 и NR12R13;
арилb представляет собой фенил, бифенил или нафтил, который, необязательно, может быть замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, ОН, галогена, CN, морфолинила, пиперидинила, -COOR12, -CONR12R13, CF3 и NR12R13
гетероарил представляет собой 5, 6, 9 или 10-членное моно- или би-циклическое ароматическое кольцо, содержащее, где это возможно, 1, 2 или 3 кольцевых члена, независимо выбранных из N, NR12, S и О; гетероарил, необязательно, может быть замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, ОН, галогена, CN, морфолинила, пиперидинила, арила, -(CH2)1-3-арила, гетероарилаb, -COOR12, -CONR12R13, CF3 и NR12R13;
гетероарилb представляет собой 5, 6, 9 или 10-членное моно- или би-циклическое ароматическое кольцо, содержащее, где это возможно, 1, 2 или 3 кольцевых члена, независимо выбранных из N, NR12, S и О; при этом гетероарилb, необязательно, может быть замещен 1, 2 или 3 заместителями, независимо выбранными из
алкила, алкокси, ОН, галогена, CN, морфолинила, пиперидинила, арила, -(СН2)1-3-арила, -COOR12, -CONR12R13, CF3 и NR12R13;
R12 и R13 независимо выбраны из Н и алкила; или R12 и R13 вместе с азотом, с которым они связаны, образуют 4-, 5-, 6- или 7-членное гетероциклическое кольцо, которое может быть насыщенным или ненасыщенным с 1 или 2 двойными связями
R14 и R15 вместе с азотом, с которым они связаны, образуют 4-, 5-, 6- или 7-членное гетероциклическое кольцо, которое может быть насыщенным или ненасыщенным с 1 или 2 двойными связями, и необязательно может быть оксо-замещенным;
где
когда R5, R6 и R7 отсутствуют или представляют собой Н, тогда:
или
R10 и R11 вместе образуют циклоалкильное кольцо или циклический эфир;
или
А представляет собой арил, и арил представляет собой фенил, бифенил или нафтил, замещенный 1, 2 или 3 заместителями, независимо выбранными из ОН, гетероарила, арилаb, -O-арилаb, -(СН2)1-3-арилаb, -(СН2)1-3-гетероарила, -COOR12, -CONR12R13 и -(СН2)3-NR14R15; где,
арилb представляет собой фенил, бифенил или нафтил, при этом арилb замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, ОН, галогена, CN, морфолинила, пиперидинила, -COOR12, -CONR12R13, CF3 и NR12R13; и
гетероарил представляет собой 5, 6, 9 или 10-членное моно- или би-циклическое ароматическое кольцо, содержащее, где это возможно, 1, 2 или 3 кольцевых члена, независимо выбранных из N, NR12, S и О, при этом гетероарил замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, галогена, CN, арила, морфолинила, пиперидинила, -(СН2)1-3-арила, гетероарилаb, -COOR12, -CONR12R13, CF3 и -NR12R13;
или
А представляет собой гетероарил, и гетероарил представляет собой 5, 6, 9 или 10-членное моно- или би-циклическое
ароматическое кольцо, содержащее, где это возможно, 1, 2 или 3 кольцевых члена, независимо выбранных из N, NR12, S и О, при этом гетероарил замещен 1, 2 или 3 заместителями, независимо выбранными из арила, -(СН2)1-3-арила, гетероарилаb, -COOR12 и -CONR12R13; где
арил представляет собой фенил, бифенил или нафтил, при этом арил замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, ОН, галогена, CN, морфолинила, пиперидинила, гетероарила, арилаb, -O-арилаb, -(СН2)1-3-арилаb, -(CH2)1-3-гетероарила, -COOR12, -CONR12R13, -COR12R13, -(СН2)1-3-NR14R15, CF3 и -NR12R13; и
гетероарилb представляет собой 5, 6, 9 или 10-членное моно- или би-циклическое ароматическое кольцо, содержащее, где это возможно, 1, 2 или 3 кольцевых члена, независимо выбранных из N, NR12, S и О, при этом гетероарилb замещен 1, 2 или 3 заместителями, независимо выбранными из алкила, алкокси, галогена, CN, морфолинила, пиперидинила, арила, -(СН2)1-3-арила, -COOR12, -CONR12R13, CF3 и NR12R13;
и его таутомеры, изомеры, стереоизомеры (включая энантиомеры, диастереоизомеры и их рацемические и скалемические смеси), фармацевтически приемлемые соли и сольваты.
2. Соединение по п. 1, где по меньшей мере один из R5, R6 и R7 выбран из алкила, галогена, арила, гетероарила и CF3.
3. Соединение по п. 1 или 2, где А выбран из:
4. Соединение по п. 1 или 2, где А представляет собой:
5. Соединение по п. 1, где R5, R6 и R7 отсутствуют или представляют собой Н; и А выбран из:
6. Соединение по п. 1 или 2, где X представляет собой N и W, Y и Z представляют собой С.
7. Соединение по п. 6, где R5 представляет собой Н, и R6 и R7 представляют собой метил.
8. Соединение по п. 1 или 2, где X и Y представляют собой N, и W и Z представляют собой С.
9. Соединение по п. 1 или 2, где X, Y и Z представляют собой N, и W представляет собой С.
10. Соединение по п. 1 или 2, где R8 и R9 представляют собой Н.
11. Соединение п. 1 или 2, где:
W представляет собой С;
X представляет собой N;
Y представляет собой С;
Z представляет собой С;
R5 представляет собой Н;
R6 и R7 представляют собой СН3;
R8 и R9 представляют собой Н; и
R10 и R11 оба представляют собой Н или вместе образуют циклопропановое кольцо.
12. Соединение по п. 1 или 2, где V представляет собой С.
13. Соединение по п. 1 или 2, где R1 выбран из алкила, алкокси, CN, галогена и CF3.
14. Соединение по п. 1 или 2, где R1 представляет собой алкил.
15. Соединение по п. 1 или 2, где R3 представляет собой алкил.
16. Соединение по п. 1, выбранное из следующих:
4-аминометил-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-(1-амино-циклопропил)бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-бензиламид 2,5-диметил-1-(6-фенил-пиридин-2-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-бензиламид 1-[2-(3-фтор-фенил)тиазол-4-илметил]-2,5-диметил-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-бензиламид 2,5-диметил-1-(2-тиофен-3-ил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
(6-аминометил-пиридин-3-илметил)амид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-3-фтор-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-фтор-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-хлор-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-трифторметил-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-метокси-бензиламид 2,5-диметил-1-(2-фенил-тиазол-4-илметил)-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-бензиламид 1-[4-(3,5-диметил-пиразол-1-илметил)бензил]-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-бензиламид 2,5-диметил-1-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 2,5-диметил-1-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 1-этил-4-метил-5-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 2,5-диметил-1-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-этил-4-метил-5-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-бензиламид 2,5-диметил-1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-бензиламид 2,5-диметил-1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 1-этил-4-метил-5-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 2,5-диметил-1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-3-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-этил-4-метил-5-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-имидазол-4-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 1-[4-(4-метил-пиразол-1-
илметил)бензил]-1Н-имидазол-4-карбоновой кислоты;
4-аминометил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-[1,2,3]триазол-4-карбоновой кислоты;
4-аминометил-2-метил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)-бензил]-1Н-[1,2,3]триазол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-имидазол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-[1,2,3]триазол-4-карбоновой кислоты;
4-аминометил-бензиламид 1-этил-4-метил-5-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-бензиламид 1-этил-4-метил-5-[4-(2-оксо-2Н-пиридин-1-илметил)бензил]-1Н-пиррол-2-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 5-метил-1-[4-(4-метил-пиразол-1-илметил)бензил]-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-3-фтор-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-3-трифторметил-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-3-трифторметил-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-3-фтор-2-метил-бензиламид 1-[4-(4-метил-пиразол-1-илметил)бензил]-3-трифторметил-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 3-метил-1-(2-метил-хинолин-6-илметил)-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 5-метил-1-(2-метил-хинолин-6-илметил)-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-(2-метил-хинолин-6-илметил)-3-трифторметил-1Н-пиразол-4-карбоновой кислоты;
4-аминометил-2,6-диметил-бензиламид 1-(2-пирролидин-1-ил-пиридин-4-илметил)-3-трифторметил-1Н-пиразол-4-карбоновой кислоты;
и их фармацевтически приемлемых солей и сольватов.
17. Фармацевтическая композиция, содержащая соединение по
любому из пп. 1-16 и фармацевтически приемлемый носитель, разбавитель или эксципиент.
18. Применение соединения по любому из пп. 1-16 в медицине.
19. Применение соединения по любому из пп. 1-16 для получения лекарственного средства для лечения или профилактики заболевания или состояния, в которое вовлечена активность плазменного калликреина.
20. Способ лечения заболевания или состояния, в которое вовлечена активность плазменного калликреина, включающий введение субъекту, нуждающемуся в этом, терапевтически эффективного количества соединения по любому из пп. 1-16.
21. Применение соединения по любому из пп. 1-16 в способе лечения заболевания или состояния, в которое вовлечена активность плазменного калликреина.
22. Применение по п. 19 или 21, где заболевание или состояние, в которое вовлечена активность плазменного калликреина, выбрано из ухудшения остроты зрения, диабетической ретинопатии, диабетического макулярного отека, наследственной ангиоэдемы, диабета, панкреатита, кровоизлияния в мозг, нефропатии, кардиомиопатии, нейропатии, воспалительного заболевания кишечника, артрита, воспаления, септического шока, гипотензии, рака, респираторного дистресс-синдрома взрослых, диссеминированного внутрисосудистого свертывания, хирургической операции с искусственным кровообращением и кровотечения, вызванного пост-оперативным вмешательством.
23. Применение по п. 19 или 21, где заболевание или состояние, в которое вовлечена активность плазменного калликреина, представляет собой ретинальную сосудистую проницаемость, связанную с диабетической ретинопатией и диабетическим макулярным отеком.
24. Способ по п. 20, где заболевание или состояние, в которое вовлечена активность плазменного калликреина, выбрано из ухудшения остроты зрения, диабетической ретинопатии, диабетического макулярного отека, наследственной ангиоэдемы, диабета, панкреатита, кровоизлияния в мозг, нефропатии, кардиомиопатии, нейропатии, воспалительного заболевания
кишечника, артрита, воспаления, септического шока, гипотензии, рака, респираторного дистресс-синдрома взрослых, диссеминированного внутрисосудистого свертывания, хирургической операции с искусственным кровообращением и кровотечения, вызванного пост-оперативным вмешательством.
25. Способ по п. 20, где заболевание или состояние, в которое вовлечена активность плазменного калликреина, представляет собой ретинальную сосудистую проницаемость, связанную с диабетической ретинопатией и диабетическим макулярным отеком.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750074P | 2013-01-08 | 2013-01-08 | |
GB1300304.1 | 2013-01-08 | ||
US61/750,074 | 2013-01-08 | ||
GBGB1300304.1A GB201300304D0 (en) | 2013-01-08 | 2013-01-08 | Benzylamine derivatives |
US201361865732P | 2013-08-14 | 2013-08-14 | |
US61/865,732 | 2013-08-14 | ||
PCT/GB2014/050043 WO2014108679A1 (en) | 2013-01-08 | 2014-01-08 | Benzylamine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2015133171A true RU2015133171A (ru) | 2017-02-15 |
RU2660421C2 RU2660421C2 (ru) | 2018-07-06 |
Family
ID=47748123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015133171A RU2660421C2 (ru) | 2013-01-08 | 2014-01-08 | Бензиламиновые производные |
Country Status (18)
Country | Link |
---|---|
US (1) | US9670157B2 (ru) |
EP (1) | EP2943483B1 (ru) |
JP (1) | JP6430398B2 (ru) |
KR (1) | KR102185928B1 (ru) |
CN (1) | CN105143201B (ru) |
AU (1) | AU2014204666B2 (ru) |
BR (1) | BR112015016293B1 (ru) |
CA (1) | CA2897273C (ru) |
ES (1) | ES2623895T3 (ru) |
GB (1) | GB201300304D0 (ru) |
HU (1) | HUE033243T2 (ru) |
MX (1) | MX362889B (ru) |
MY (1) | MY182590A (ru) |
NZ (1) | NZ709609A (ru) |
PL (1) | PL2943483T3 (ru) |
RU (1) | RU2660421C2 (ru) |
SG (1) | SG11201505309TA (ru) |
WO (1) | WO2014108679A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2766346T3 (pl) | 2011-10-14 | 2017-09-29 | Bristol-Myers Squibb Company | Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA |
SI2906551T1 (en) | 2012-10-12 | 2018-05-31 | Bristol-Myers Squibb Company | CRYSTALINOUS FORMATS OF XIA FACTOR INHIBITOR |
US9315519B2 (en) | 2012-10-12 | 2016-04-19 | Bristol-Myers Squibb Company | Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
WO2014059214A1 (en) | 2012-10-12 | 2014-04-17 | Bristol-Myers Squibb Company | Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
EP2978751B1 (en) | 2013-03-25 | 2018-12-05 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
WO2015022546A1 (en) * | 2013-08-14 | 2015-02-19 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
HUE040226T2 (hu) | 2014-01-31 | 2019-02-28 | Bristol Myers Squibb Co | Makrociklusok heterociklusos P2' csoportokkal XIA faktor inhibitorokként |
NO2760821T3 (ru) | 2014-01-31 | 2018-03-10 | ||
WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
AR106241A1 (es) | 2015-10-01 | 2017-12-27 | Biocryst Pharm Inc | Inhibidores de calicreína plasmática humana |
GB201609519D0 (en) * | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
US11168080B2 (en) | 2017-04-26 | 2021-11-09 | Mitobridge, Inc. | Dynamin-1-like protein inhibitors |
GB201719882D0 (en) * | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
RU2020121151A (ru) * | 2017-11-29 | 2021-12-29 | Калвиста Фармасьютикалз Лимитед | Дозированные формы, содержащие ингибитор плазменного калликреина |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
AU2019462140A1 (en) | 2019-08-21 | 2022-02-24 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
EP4017850A1 (en) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
RU2734970C1 (ru) * | 2019-12-10 | 2020-10-26 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" | Система доставки 2-этил-6-метил-3-гидроксипиридина сукцината для перорального применения в форме гастроретентивной таблетки |
US11091447B2 (en) | 2020-01-03 | 2021-08-17 | Berg Llc | UBE2K modulators and methods for their use |
TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
US20230381162A1 (en) | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
US20240122909A1 (en) | 2021-02-09 | 2024-04-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
CN115073429A (zh) * | 2021-03-15 | 2022-09-20 | 昆药集团股份有限公司 | 一种1,2,4-三嗪-3,5-二酮类化合物的盐型、晶型及其制备方法 |
WO2023002219A1 (en) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
WO2023185634A1 (zh) * | 2022-03-30 | 2023-10-05 | 南京明德新药研发有限公司 | 作为血浆激肽释放酶抑制剂的杂环类化合物 |
WO2023209381A1 (en) | 2022-04-27 | 2023-11-02 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
OA11599A (en) * | 1998-08-20 | 2004-08-23 | Agouron Pharma | Non-peptide GnRH agents, methods and intermediatesfor their preparation. |
US7101878B1 (en) * | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
US7247654B2 (en) * | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
EP3168304A1 (en) | 2003-08-27 | 2017-05-17 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
KR20080087817A (ko) * | 2005-12-14 | 2008-10-01 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 xia 억제제로서 아릴프로피온아미드,아릴아크릴아미드, 아릴프로핀아미드 또는 아릴메틸우레아유사체 |
EP1966141A1 (en) * | 2005-12-14 | 2008-09-10 | Brystol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
CA2658523C (en) * | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
CN102026996B (zh) * | 2008-03-13 | 2015-01-07 | 百时美施贵宝公司 | 作为凝血因子xia抑制剂的哒嗪衍生物 |
EP2512466A4 (en) | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
CN102858744B (zh) | 2010-01-28 | 2015-03-04 | 医药公司(莱比锡)有限公司 | 胰蛋白酶样丝氨酸蛋白酶抑制剂及其制备方法和用途 |
JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
WO2012004678A2 (en) | 2010-07-07 | 2012-01-12 | The Medicines Company (Leipzig) Gmbh | Serine protease inhibitors |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
ES2636312T3 (es) * | 2011-04-12 | 2017-10-05 | VIIV Healthcare UK (No.5) Limited | Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH |
WO2012142308A1 (en) * | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
WO2013111108A1 (en) * | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
CA2894642A1 (en) | 2013-01-08 | 2014-07-17 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
-
2013
- 2013-01-08 GB GBGB1300304.1A patent/GB201300304D0/en not_active Ceased
-
2014
- 2014-01-08 BR BR112015016293-2A patent/BR112015016293B1/pt active IP Right Grant
- 2014-01-08 NZ NZ709609A patent/NZ709609A/en unknown
- 2014-01-08 AU AU2014204666A patent/AU2014204666B2/en active Active
- 2014-01-08 RU RU2015133171A patent/RU2660421C2/ru active
- 2014-01-08 ES ES14700111.9T patent/ES2623895T3/es active Active
- 2014-01-08 PL PL14700111T patent/PL2943483T3/pl unknown
- 2014-01-08 MX MX2015008835A patent/MX362889B/es active IP Right Grant
- 2014-01-08 JP JP2015551223A patent/JP6430398B2/ja active Active
- 2014-01-08 MY MYPI2015702197A patent/MY182590A/en unknown
- 2014-01-08 CN CN201480011941.3A patent/CN105143201B/zh active Active
- 2014-01-08 SG SG11201505309TA patent/SG11201505309TA/en unknown
- 2014-01-08 US US14/759,542 patent/US9670157B2/en active Active
- 2014-01-08 HU HUE14700111A patent/HUE033243T2/hu unknown
- 2014-01-08 CA CA2897273A patent/CA2897273C/en active Active
- 2014-01-08 KR KR1020157021439A patent/KR102185928B1/ko active IP Right Grant
- 2014-01-08 WO PCT/GB2014/050043 patent/WO2014108679A1/en active Application Filing
- 2014-01-08 EP EP14700111.9A patent/EP2943483B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9670157B2 (en) | 2017-06-06 |
BR112015016293B1 (pt) | 2022-10-18 |
HUE033243T2 (hu) | 2017-11-28 |
WO2014108679A1 (en) | 2014-07-17 |
SG11201505309TA (en) | 2015-08-28 |
BR112015016293A2 (pt) | 2017-07-11 |
MY182590A (en) | 2021-01-26 |
AU2014204666A1 (en) | 2015-07-23 |
EP2943483B1 (en) | 2017-03-01 |
CN105143201A (zh) | 2015-12-09 |
PL2943483T3 (pl) | 2017-08-31 |
US20160039752A1 (en) | 2016-02-11 |
ES2623895T3 (es) | 2017-07-12 |
KR20150115791A (ko) | 2015-10-14 |
JP6430398B2 (ja) | 2018-11-28 |
JP2016504378A (ja) | 2016-02-12 |
CA2897273C (en) | 2021-05-18 |
KR102185928B1 (ko) | 2020-12-02 |
MX2015008835A (es) | 2016-02-05 |
CN105143201B (zh) | 2019-02-22 |
NZ709609A (en) | 2020-07-31 |
CA2897273A1 (en) | 2014-07-17 |
MX362889B (es) | 2019-02-22 |
EP2943483A1 (en) | 2015-11-18 |
GB201300304D0 (en) | 2013-02-20 |
RU2660421C2 (ru) | 2018-07-06 |
AU2014204666B2 (en) | 2017-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015133171A (ru) | Бензиламиновые производные | |
JP2016504378A5 (ru) | ||
RU2015154987A (ru) | Гетероциклические производные | |
JP2016519156A5 (ru) | ||
JP2020033357A5 (ru) | ||
RU2017122364A (ru) | N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина | |
RU2018140092A (ru) | Новые пиразолпиримидиновые производные | |
DK2531191T3 (en) | Sigma ligands for use in the prevention and / or treatment of post-operative pain | |
RU2016108753A (ru) | Ингибиторы ферментов | |
RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
JP2016528245A5 (ru) | ||
RU2430923C2 (ru) | Тиазолилдигидрохиназолины | |
RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
JP2013503901A5 (ru) | ||
AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
JP2010513272A5 (ru) | ||
JP2015526519A5 (ru) | ||
RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
BRPI0614262A2 (pt) | aril piridinas e métodos para uso das mesmas | |
RU2015127822A (ru) | Ингибиторы энхансера гомолога 2 белка zeste | |
JP2019537603A5 (ru) | ||
RU2014142328A (ru) | Производные пиперидина в качестве агонистов gpr119 | |
RU2009117705A (ru) | Производные 2-аминокарбонилпиридина |